9 Best Gene Therapy Stocks to Buy Now

2. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 63

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biotechnology company, based in Westchester County, New York. The stock ranks second on our list of best gene therapy stocks to buy now.

Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) collaboration with Intellia on CRISPR gene editing is making progress. Patient enrollment has started in the Phase 3 MAGNITUDE study of [Intellia-2001] (ph) for a lead indication of TTR amyloidosis with cardiomyopathy. This is the first in vivo CRISPR program that has been cleared to enter Phase 3 studies in the US. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is also expected to become the first company using CRISPR technology to insert a corrective gene in vivo to treat a deficiency disease.

Furthermore, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) aims to introduce more auditory gene therapy programs in the following years. These programs will be treating more common forms of monogenic hearing loss.

Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) average price target is $1,061, taken from 18 analysts’ 12-month projections shared within the last 3 months. The highest target stands at $1,185, while the lowest forecast is $720. On average, this reflects an 8.3% upside potential from the current price of $980.

At the end of Q1 2024, 63 hedge funds reported owning a stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). D E Shaw is the leading hedge fund investor in the company, with a stake worth over $221 million.